DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

NEXUS KNOWLEDGE PUBLICATION

https://nknpub.com/index.php/1

Advanced Pharmacology-I

ISBN Number- 978-81-985724-9-3

Chapter- 5



AUTOCOID PHARMACOLOGY

SUJIT RAMCHANDRA DESHMUKH
Graduate Student
Pusan National University, South Korea
Pin - 46241
Email: deshmukhsujit540@gmail.com

MAYURI SHATRUGHNA GHADGE
Msc. Organic chemistry
Yashvantrao Chavan Institute of Science
Satara, Maharashtra, India
Pin - 415019
Email: mayurighadge885@gmail.com

DR. RAKESH SAHEBRAO JADHAV
Professor & H.O.D.
GES's Sir Dr. M.S. Gosavi College of Physiotherapy, India
Nashik, Maharashtra
Email: drrakeshsj@gmail.com

ARPIT GAWSHINDE
Assistant Professor
BM College of Pharmaceutical Education and Research, Indore
Email: arpitgawshinde95@gmail.com

DR. MUKESH KUMAR MEENA
Assistant Professor
Department of Pharmaceutical Sciences,
Mohanlal Sukhadia University,
Udaipur, Rajasthan, 313001
Email: mukesh_meena27@mlsu.ac.in

Published By – Nexus Knowledge Publication

(Imprint of AKT Multitask Consultancy)

Bilaspur, Chhattisgarh, India, 495006

www.aktmultitask.com

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

Chapter 5…

AUTOCOID PHARMACOLOGY

SUJIT RAMCHANDRA DESHMUKH
Graduate Student
Pusan National University, South Korea
Pin - 46241
Email: deshmukhsujit540@gmail.com

MAYURI SHATRUGHNA GHADGE
Msc. Organic chemistry
Yashvantrao Chavan Institute of Science Satara, Maharashtra, India
Pin - 415019
Email: mayurighadge885@gmail.com

DR. RAKESH SAHEBRAO JADHAV
Professor & H.O.D.
GES's Sir Dr. M.S. Gosavi College of Physiotherapy, India
Nashik, Maharashtra
Email: drrakeshsj@gmail.com

ARPIT GAWSHINDE
Assistant Professor
BM College of Pharmaceutical Education and Research, Indore
Email: arpitgawshinde95@gmail.com

DR. MUKESH KUMAR MEENA
Assistant Professor
Department of Pharmaceutical Sciences, Mohanlal Sukhadia University,
Udaipur, Rajasthan, 313001
Email: mukesh_meena27@mlsu.ac.in

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

Autocoids are a heterogeneous group of locally acting biologically active molecules produced and secreted by cells in response to a wide range of physiological and pathological stimuli. In contrast to classical hormones, which are produced by endocrine glands and delivered through the bloodstream to remote organs or tissues, autocoids mainly exert their effects at or near the site of their production. This feature makes autocoids produce quick and fleeting effects, often of a key importance to the control of diverse physiological activities and to dealing with acute pathology. The suffix "-coid" in autocoid is constructed from the Greek prefix "auto" (meaning self) and suffix "-coid" (meaning like), as they are said to be active at or close to where they are being synthesized. Autocoids are important in the regulation of processes including inflammation, pain, fever, vascular tone, smooth muscle contraction, allergic response, and hemostasis. They may exert actions ranging from vasodilation and blood flow regulation to the induction of pain and promotion of immune responses [1]. Autocoids are frequently synthesized in response to external stimuli such as injury, infection, or allergy and immediately take action to trigger or terminate physiological responses.

A number of classes of autocoids have been described, each with unique but complementary functions in the body. Histamine is one of the most well-known autocoids and is responsible for inflammatory reactions, especially allergic reactions, where it is responsible for causing itching, swelling, and vasodilation. Histamine release occurs upon binding of allergens to IgE antibodies on mast cells, resulting in histamine release from these cells. The action of histamine is largely mediated by its receptors, H1 and H2, which take part in vascular permeability, bronchoconstriction, and gastric acid secretion. Serotonin (5-hydroxytryptamine, or 5-HT), on the other hand, is another significant autocoid, mainly located in the gastrointestinal tract and central nervous system [2]. It functions crucially in the mood regulation, appetite, and contraction of smooth muscle. In addition, serotonin plays a part in the regulation of blood clotting by facilitating platelet aggregation. It also serves as a neurotransmitter, affecting pain mechanisms, mood stabilization, and gastrointestinal motility. The kinins, including bradykinin and kallidin, are powerful vasodilators and increase vascular permeability and are thus significant mediators of inflammation. They also induce pain by their effect on pain receptors and produce conditions like angioedema.

Yet another essential class of autocoids is prostaglandins, which are produced by the metabolism of arachidonic acid by the cyclooxygenase (COX) pathway. Prostaglandins participate in many functions, such as the regulation of inflammation, fever, pain, vascular tone, and renal function. Prostaglandins have a key role in initiating inflammation due to injury

or infection and are responsible for swelling [3], redness, and pain. Certain prostaglandins like PGE2 are implicated in inducing fever in response to the body's inflammatory response, and others regulate circulation in organs like the kidneys and the lungs. Inflammatory ailments like arthritis often arise due to the overproduction of prostaglandins and hence drugs such as NSAIDs (nonsteroidal anti-inflammatory drugs) inhibiting COX enzymes are prescribed to manage the symptoms by blocking prostaglandin synthesis. Finally, opioid peptides like endorphins and enkephalins interact with opioid receptors in the central nervous system to control pain perception and offer natural pain relief. The peptides are part of the body's natural pain control systems and also affect mood and stress response [4].

Pharmacological intervention of autocoids and their receptors has significant therapeutic implications in the management of numerous medical conditions. Autocoid-targeting drugs are commonly applied in clinical settings to treat allergies, asthma, peptic ulcers, migraines, inflammatory disorders, and pain relief. For example, antihistamines find widespread use as a treatment for allergic diseases in blocking histamine effects, and serotonin reuptake inhibitors (SSRIs) are administered as antidepressants to modulate serotonin levels within the brain. Prostaglandin inhibitors such as NSAIDs are extensively prescribed to cure pain and inflammation, and bradykinin antagonists are currently being designed for the treatment of diseases such as angioedema [5]. In the case of opioid peptides, opioid analgesics are often used for the control of severe pain, although they are well regulated because of dependence potential and side effects. Additionally, with the better understanding of autocoid systems, new therapeutic approaches are being sought to control their action in a more selective and controlled way with less side effects and more therapeutic gain.

Autocoids are key regulators of numerous physiological and disease processes. Due to their immediate and localized effect, they represent the perfect target for pharmacologic intervention, and drugs that act on them are critical therapeutic tools in the treatment of many disorders. Through their comprehension of various autocoids such as histamine, serotonin, kinins, prostaglandins, and opioid peptides, health care workers can better manage diseases from acute allergic responses to pain and inflammation.

5.1. PHYSIOLOGICAL AND PATHOLOGICAL ROLE OF AUTOCOIDS

Autocoids are bioactive substances with local action that are involved in key roles in numerous physiological and pathological processes within the body. They differ from systemic hormones, which are produced and secreted by endocrine glands and distributed through the blood to have

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

an effect on far-removed organs or tissues, as they are produced and secreted locally at the site of action so they can have fast and highly localized effects. These chemicals are synthesized upon specific stimuli, usually inflammation, injury, or infection, and exert their effects locally before they are rapidly broken down. Because of their speedy synthesis, action, and breakdown, autocoids play a critical role in homeostasis of many systems and are implicated in the regulation of inflammation, vascular tone [6], contraction of smooth muscles, neurotransmission, and modulation of pain. Besides their usual physiological functions, autocoids are also involved in a range of pathological conditions, where their inappropriateness in release, overproduction, or imbalance is responsible for disease development and worsening of symptoms. It is important to know the biological functions of autocoids and how they impact health and disease to formulate proper therapeutic approaches to treat diseases such as anaphylaxis, asthma, migraine, peptic ulcer disease, and chronic pain.



Figure 1: Autocoids

One of the most commonly recognized autocoids is histamine, which is a key component of immune responses, especially in allergic reactions. Histamine is produced and stored in mast cells and basophils and is released after exposure to various stimuli, such as allergens and immune responses. When released, histamine binds to histamine receptors (H1, H2, H3, and H4) on target cells, causing a myriad of physiological effects. These encompass vasodilation, enhanced vascular permeability (causing fluid loss and swelling), contraction of smooth muscle, and stimulation of sensory nerves, causing signs such as itching, pain, and inflammation. Histamine is a major mediator in disorders such as allergic rhinitis, urticaria (hives), and anaphylaxis, where uncontrolled release results in intense symptoms. In the

practice of medicine, antihistamines are also used to block histamine receptors and treat symptoms of allergy, as well as to treat more severe reactions such as anaphylaxis [7].

Another significant group of autocoids includes serotonin (5-hydroxytryptamine, 5-HT), a neurotransmitter found mainly in the central nervous system (CNS) and gastrointestinal tract. Serotonin participates in mood regulation, appetite, and sleep and also has an important role in pain modulation. Serotonin in the gastrointestinal tract is released by enterochromaffin cells and influences smooth muscle contraction and motility. In the CNS, serotonin contributes to the modulation of mood and emotional reactions, and is commonly targeted by selective serotonin reuptake inhibitors (SSRIs) in depression and anxiety disorders. Serotonin also affects vascular tone and blood clotting by stimulating platelet aggregation. Serotoninergic dysfunction underlies conditions like migraine, where serotonin levels change, resulting in vasodilation and the pain of the condition. In addition, changes in serotonin levels may also lead to gastrointestinal diseases, e.g., irritable bowel syndrome (IBS), and neuropsychiatric illnesses, e.g., schizophrenia and bipolar disorder.

Kinins, including bradykinin and kallidin, are a group of autocoids that cause inflammatory reactions. The peptides are formed by the action of the kinin-kallikrein system and act as powerful vasodilators, causing enhanced vascular permeability and edema promotion. Bradykinin also contributes to pain by directly stimulating nociceptors (pain receptors), and this causes a sensation of pain during inflammation. Consequently, kinins play a role in angioedema, painful inflammation, and cardiovascular disease. Medications that act upon the kinin system, i.e., bradykinin receptor antagonists, are being investigated as therapeutic agents for chronic pain, hypertension, and heart failure.

Another important group of autocoids is prostaglandins, which are generated by the metabolism of arachidonic acid by cyclooxygenase enzymes (COX-1 and COX-2). Prostaglandins exert a vast range of physiological actions, ranging from modulating inflammation, fever, and pain. Inflammatory prostaglandins, for example, PGE2, play a role in vasodilation, augmenting vascular permeability, and sensitizing nociceptors to painful stimuli. They are key players in conditions such as arthritis, where hyperproduction of prostaglandin results in prolonged inflammation and pain. Prostaglandins also cause fever as part of the immune response to infection by the body. Due to their implication in inflammatory mechanisms, NSAIDs (nonsteroidal anti-inflammatory drugs), which suppress COX enzymes and therefore inhibit prostaglandin synthesis, are the most frequently administered medications for managing conditions involving inflammation, including osteoarthritis, rheumatoid arthritis, and gout.

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

Lastly, opioid peptides such as endorphins, enkephalins, and dynorphins are natural pain-relieving chemicals made within the body. These peptides interact with opioid receptors in the central nervous system and peripheral tissues to block pain signals and cause feelings of euphoria and well-being. They form part of the body's own analgesic system, causing pain relief during stressful events, exercise, or injury. Yet dysregulation of this system, for example, overactivation of opioid receptors, can cause opioid addiction, tolerance, and dependence, now a major public health problem. Research on opioid peptides and their receptors has resulted in the production of both opioid analgesics (e.g., morphine, codeine) for the treatment of severe pain and opioid antagonists (e.g., naloxone) to treat opioid overdose.

5.1.1. Histamine

Histamine is a vital biogenic amine that has a central role in numerous physiological processes. Histamine is formed from the amino acid histidine by the enzyme histidine decarboxylase, mainly in mast cells, basophils, enterochromaffin-like cells (ECL) of the gastrointestinal tract, and some regions of the central nervous system (CNS). Histamine is stored in intracellular granules and is secreted when the cell is activated [8], usually following injury, infection, or allergy. When released, histamine binds to a range of target tissues, inducing both local and systemic effects that are pivotal to immune responses, gastric acid secretion regulation, and neurotransmission.

Histamine acts through four receptor subtypes: H1, H2, H3, and H4, which have differing roles in health and disease. The H1 receptor, expressed in smooth muscles, endothelial cells, and the CNS, evokes allergic reactions, including bronchoconstriction, vasodilation, and increased capillary permeability. It also plays roles in regulating sleep-wake transitions, appetite regulation, and cognition. The H2 receptor is chiefly found in gastric parietal cells, where it stimulates gastric acid secretion. It is also involved in modulating heart rate, myocardial contractility, and blood flow. The H3 receptor, on the contrary, is mainly found in the CNS and is an important presynaptic inhibitory receptor involved in the control of neurotransmitter release, with effects on alertness, cognition, and appetite. Finally, the H4 receptor is implicated in immune functions, especially in the regulation of inflammation and chemotaxis of immune cells.

The physiological functions of histamine are essential for homeostasis and defense against noxious stimuli. In the immune system, histamine is a key mediator of allergic responses, such as the symptoms of hay fever, anaphylaxis, and asthma. It also contributes importantly to the

inflammatory response by dilating vessels, which results in increased blood supply to the involved tissues so that immune cells may reach the point of injury or infection. It also controls gastric acid secretion to stimulate digestion through the facilitation of the digestion of food within the stomach. Histamine has a role within the CNS where it modulates wakefulness, arousal, and circadian rhythm.

Nonetheless, histamine may also play a role in a variety of pathological conditions. Excess production or dysregulation of histamine release can cause diseases like allergies, asthma, and chronic inflammatory disorders. The role of histamine in the formation of gastric ulcers and in disease pathogenesis in gastritis and Zollinger–Ellison syndrome demonstrate its significance in gastrointestinal physiology. In addition, inappropriate release of excess histamine in allergic responses may lead to dangerous systemic consequences such as hypotension and shock, as observed in anaphylaxis. The capacity of histamine to bind to a variety of receptor types makes it a potential target for therapeutic measures, especially in the treatment of allergic diseases, gastric ailments, and neurological disorders. Medications that affect histamine receptor function, including antihistamines and H2 antagonists, are commonly employed in the clinic to treat symptoms of histamine-related diseases:

- H1 receptors play a vital role in the mediation of allergic reactions. Upon binding of histamine to H1 receptors, it initiates a cascade of reactions such as vasodilation, bronchoconstriction, and increased vascular permeability, which are typical of allergic reactions like hay fever, urticaria (hives), and anaphylaxis. The stimulation of these receptors also leads to symptoms such as itching and edema (swelling).
- H2 receptors are mainly responsible for the control of gastric acid secretion in the stomach. Histamine binding to H2 receptors on the parietal cells of the gastric mucosa triggers the secretion of hydrochloric acid (HCl), which is necessary for digestion. Excessive activation of H2 receptors is involved in diseases like gastric hyperacidity and peptic ulcers.
- H3 receptors are present in the CNS and regulate the release of neurotransmitters such as dopamine, norepinephrine, and serotonin. Through modulation of these neurotransmitters, H3 receptors affect neurological processes such as arousal, learning, and memory.
- H4 receptors play a mainly immune function. They mediate chemotaxis (movement of immune cells to the point of infection or injury) and contribute to inflammation through

the modulation of the function of immune cells such as eosinophils, mast cells, and neutrophils.

Pathologically, histamine is the key to the development and progression of several allergic and inflammatory conditions, where its over-release causes harmful effects on several organ systems. Among the most dangerous conditions associated with histamine release is anaphylaxis, a potentially fatal allergic reaction that develops quickly after exposure to allergens like some foods, insect bites, or drugs. During anaphylaxis, the massive histamine release from basophils and mast cells causes extensive vasodilation, leading to a sudden fall in blood pressure (hypotension), which can result in shock. Histamine also causes bronchoconstriction, the constriction of airways, and breathing difficulty, a characteristic symptom of anaphylactic asthma. The anaphylaxis symptoms can advance very fast, and if left untreated, it may result in organ failure and death. Aside from anaphylaxis, histamine also plays a role in less severe but nonetheless notable allergic diseases like allergic rhinitis. During allergic rhinitis, histamine is discharged upon exposure to allergens like pollen, dust, or animal dander and triggers inflammation and irritation of the nasal passages. This results in symptoms like sneezing, itching, congestion, and rhinorrhea (runny nose), which are usually seasonal or perennial based on the allergen.

For the treatment of histamine-induced pathologies, antihistamines (H1 and H2 blockers) are commonly employed in clinical practice to inhibit the action of histamine and relieve symptoms. H1 antihistamines are employed mainly for allergic-related conditions like allergic rhinitis, urticaria (hives), and conjunctivitis. The drugs function by competitively inhibiting histamine from attaching to H1 receptors, hence diminishing symptoms such as itching, swelling, and nasal congestion. First-generation H1 antihistamines (e.g., diphenhydramine) are also capable of crossing the blood-brain barrier and inducing sedative effects, whereas second-generation H1 antihistamines (e.g., loratadine, cetirizine) are more peripherally selective for H1 receptors and are less sedating. H2 blockers (e.g., ranitidine, famotidine) are generally utilized to treat conditions associated with gastric acid hypersecretion, including gastroesophageal reflux disease (GERD) and peptic ulcers. These drugs act by inhibiting the H2 receptors on gastric parietal cells, lowering acid secretion and symptom relief of acid reflux. Combined, H1 and H2 blockers are significant therapeutic agents in the treatment of conditions in which histamine release is a key factor, providing symptomatic relief and forestalling the intensification of allergic or inflammatory reactions.

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

5.1.2. Serotonin (5-Hydroxytryptamine or 5-HT)

Serotonin, whose chemical name is 5-hydroxytryptamine (5-HT), is an important monoamine neurotransmitter that plays a vital role in the control of a vast range of physiological processes within the central nervous system (CNS) and peripheral tissues. Serotonin is produced from the amino acid tryptophan, which is ingested through foods like meat, milk, and nuts. After tryptophan is absorbed into the body, it is converted through a two-stage process: first, it is hydroxylated to produce 5-hydroxytryptophan (5-HTP), which is then decarboxylated to produce serotonin (5-HT). Although the CNS stores relatively little serotonin, much of it is sequestered in the gastrointestinal (GI) tract, namely in enterchromaffin cells [9], which comprise approximately 90-95% of the body's total serotonin. This significant store of serotonin is responsible for controlling intestinal motility, secretion, and blood flow. Serotonin also occurs in the peripheral system within platelets, which release it upon blood clotting to assist in vasoconstriction and facilitate the formation of clots.



Figure 2: Serotonin

Serotonin's multiplicity of purposes goes far beyond its function within the GI tract. Within the central nervous system (CNS), it exists as a neurotransmitter, functioning to regulate an array of crucial functions including mood, sleep-wake patterns, appetite, learning, and memory. Serotonin has been well implicated in the mood disorders for many years now, such as depression, anxiety, and bipolar disorder, given that changes in serotonin levels correspond with these mood disorders. The journey of serotonin within the CNS starts with its formation

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

in serotonergic neurons found in the brainstem raphe nuclei. They project extensively to other areas of the brain such as the limbic system responsible for emotion and memory, as well as the hypothalamus, which is responsible for regulating physiological processes like hunger, thirst, and body rhythms. The level of serotonin in the brain is tightly controlled and can be affected by genetics, hormone fluctuations, and environmental stressors.

Another significant feature of serotonin's mechanism is its participation in the enteric nervous system, commonly called the "second brain" because of its extensive neural network responsible for governing a large part of the gastrointestinal system independently of the CNS. Serotonin that is released from enteric neurons and chromaffin cells controls intestinal motility by modulating the contraction and relaxation of smooth muscle, hence the movement of food through the digestive system. Additionally, serotonin participates in the secretion of digestive enzymes and fluids, which aid in proper digestion. It also plays an important role in the control of blood supply to the intestines, causing vasodilation under specific conditions. Aside from its role in GI functions, serotonin's involvement in vascular tone is also important since it can cause both vasodilation and vasoconstriction, depending on the receptor it acts upon. As an instance, serotonin that is released from platelets upon injury is capable of causing vasoconstriction, which aids in the clotting of blood.

But serotonin's function is not limited to these conventional roles, for it has been found to modulate a number of other physiological processes, such as pain sensation, thermoregulation, and sexual activity. Its receptors, of which there are numerous subtypes (e.g., 5-HT1, 5-HT2, 5-HT3), are found diffusely in the body and are engaged in various pathways based on their site of location. For example, 5-HT3 receptors are involved in nausea and vomiting; 5-HT1 receptors in mood regulation and are the target for numerous antidepressant drugs like selective serotonin reuptake inhibitors (SSRIs). Knowledge of the multifaceted actions of serotonin in different systems underlines its status as a multifunctional molecule with wide-ranging effects that shape both normal physiological function and disease processes.

Serotonin plays multifaceted physiological functions, mediating through a number of receptors (5-HT1 to 5-HT7) spread throughout different tissues, organs, and systems:

- In the CNS, serotonin is also important for regulating mood, emotions, cognition, sleep, and appetite. Serotonin dysregulation in the brain is associated with psychiatric illnesses like depression, anxiety, and bipolar disorder.

- Serotonin in the GI tract increases intestinal motility and peristalsis, facilitating the movement of food through the digestive system. It also controls intestinal secretion, which aids in normal digestion.
- In vascular tissues, serotonin may serve as a vasoconstrictor or vasodilator, depending upon the receptor subtype. For instance, in the cerebral vasculature, serotonin may cause vasoconstriction, which leads to migraine headache.

Serotonin is intimately implicated in the pathophysiology of many neurological and gastrointestinal diseases, with its activity and levels being at the center of the expression of a number of disorders. Perhaps one of the most well-known is migraine, a neurological disease involving frequent headaches that are frequently accompanied by nausea and vomiting. Serotonin's implication in migraine is especially interesting because changes in serotonin levels have a direct impact on the vascular system and pain pathways. During an attack of migraine, a reduction in serotonin levels is believed to initiate vasodilation (widening of the blood vessels), especially in the cerebral vasculature, resulting in the typical throbbing headache. Vasodilation is believed to stimulate the pain receptors in the brain and its surrounding tissues. Serotonin also has a role in the central pain pathway, regulating the perception of pain. Therefore, drug therapies that try to restore a balance of serotonin, like the 5-HT receptor agonists, are common in aborting acute migraine attack. Triptans like sumatriptan are selective agonists of 5-HT1 receptors that operate by causing dilation of dilated blood vessels to close and block the release of pro-inflammatory neuropeptides to relieve migraine pain.

In depression and anxiety disorders, serotonin dysfunction is at the center of the pathophysiology. Both conditions are linked with compromised serotonin signaling in the central nervous system (CNS), especially in areas like the limbic system, which is responsible for emotion and mood. In depression, there is commonly a lack of serotonin availability in the synaptic cleft, such that serotonin cannot efficiently convey signals between neurons. This disturbance in serotonin signaling may produce symptoms of sustained sadness, anhedonia (lack of interest in enjoyable activities), and cognitive dysfunction. Likewise, in the anxiety disorders, diminished serotonin levels or compromised function of serotonin in the brain can result in a sense of pervasive worry, fear, and nervousness. For treatment of these neurochemical disturbances, selective serotonin reuptake inhibitors (SSRIs) [10], like fluoxetine and sertraline, are most often used. SSRIs exert their effects by inhibiting serotonin reuptake into the presynaptic neuron, thus making more serotonin available in the synaptic cleft and enhancing interneuronal communication. These drugs are regarded as first-line drugs for

depression and anxiety disorders because of their efficacy and relative safety compared to older antidepressants such as tricyclics.

A further disorder in which serotonin is critical is carcinoid syndrome, which is a rare and unusual disease caused by the production of tumors that secrete serotonin, and usually they occur in the lung or gastrointestinal tract. The secretion of these so-called carcinoid tumors into excess serotonin in the bloodstream results in a complex disorder that is simply termed carcinoid syndrome. The most prevalent symptoms are flushing, diarrhea, and cardiac dysfunction, leading to valvular heart disease and heart valve fibrosis. Release of excess amounts of serotonin involves several systems, such as the vascular system (causing flushing through vasodilation) and the gastrointestinal tract (causing increased motility and diarrhea). Since serotonin also acts on the heart and vessels, excess serotonin can cause heart valve injury. Treatment of carcinoid syndrome is most commonly with medications that inhibit serotonin's effects, such as the somatostatin analog octreotide, which prevents release of serotonin and other bioactive peptides from tumors. In some instances, the 5-HT3 receptor blockers ondansetron can be used to control diarrhea and other GI complaints.

Therapeutic action on serotonin receptors is not limited to depression, anxiety, and carcinoid syndrome. For instance, 5-HT3 antagonists like ondansetron are often used to stop nausea and vomiting induced by chemotherapy. Chemotherapy agents tend to cause nausea and vomiting by triggering serotonin receptors in the gastrointestinal system and the chemoreceptor trigger zone in the brainstem. Through the blockade of 5-HT3 receptors, which are implicated in the vomiting reflex, ondansetron and other drugs decrease these side effects, dramatically enhancing the health-related quality of life in cancer patients receiving chemotherapy. Equally, the introduction of 5-HT1 receptor agonists, like triptans, shows the wide therapeutic scope of serotonin modulation in different disease states [11]. The role of serotonin in gastrointestinal motility, vascular tone, and pain pathways underpins its diverse clinical applications, and ongoing research into serotonin signaling continues to uncover new therapeutic avenues for treating both common and rare disorders.

5.1.3. Kinins (Bradykinin and Kallidin)

Kinins are biologically active peptides that are involved in the regulation of vascular tone, inflammation, and pain. They are formed by the enzymatic cleavage of kininogens by kallikrein enzymes, which split the larger kininogen molecule into smaller active peptides. The two major kinins formed are bradykinin and kallidin, both of which mediate their physiological effects

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

mainly through two receptor subtypes: B1 and B2 receptors. These receptors have a broad presence in different tissues and are significantly involved in modulating inflammatory as well as vascular responses.



Figure 3: Classification of Kinins (Bradykinin and Kallidin)

a) B2 Receptors and Physiological Effects

The B2 receptors are the more abundant, constitutively expressed receptors found in most tissues under normal physiologic circumstances. These receptors are responsible for mediating the traditional, useful effects of the kinins such as vasodilation, increase in vascular permeability, and induction of pain. Upon bradykinin or kallidin's binding to the B2 receptors, they result in vasodilation, causing relaxation of the vascular smooth muscle and dilation of the blood vessels. This vasodilation results in decreased blood pressure and is an integral part of the body's cardiovascular control [12]. Kinin action also enhances the permeability of blood vessel walls so that proteins, white blood cells, and fluid leak into the tissue around the vessels, adding to edema (swelling) and inflammation. This heightened vascular permeability is important in immune responses because it helps enable immune cells and proteins to reach areas of infection or injury. Excessive, however, will add too much fluid to areas, worsen inflammation and injury to tissue.

b) B1 Receptors and Inflammatory Responses

The B1 receptors, on the other hand, are not expressed under normal conditions but are upregulated in the presence of inflammatory states, tissue damage, or infection. Stimulation of the B1 receptors in such pathologic conditions causes an enhancement of the inflammatory process. The B1 receptors are usually linked to more chronic or sustained inflammatory states. Activation of the B1 receptors results in increased pain and swelling, adding to the exacerbation of the condition. This upregulation and activation of B1 receptors by stressors such as injury

or infection function to enhance the inflammatory response, enhancing the production of pro-inflammatory cytokines and other mediators. Thus, activation of B1 receptors can worsen diseases such as rheumatoid arthritis, osteoarthritis, and other chronic inflammatory diseases, where pain and swelling are characteristic symptoms.

c) Pathophysiological Role of Bradykinin

Bradykinin, in fact, is a very powerful mediator of pain and vasodilation, and an excess of bradykinin has been shown to play a role in numerous pathological states. A case in point is angioedema, a state where there is swelling of the deeper tissues of the skin (usually of the lips and around the eyes), which is usually found in association with an excess of bradykinin. Swelling in the throat is potentially lethal and causes respiratory distress.

The condition is usually worsened by the use of angiotensin-converting enzyme (ACE) inhibitors, which are a class of medication used for the treatment of hypertension as well as heart failure. ACE inhibitors inhibit the enzyme responsible for breaking down bradykinin, and thereby they cause bradykinin levels to rise. The resulting increase causes the side effects like dry cough, angioedema, and even hypotension in some patients. The bradykinin in excess can also cause hypotension as a result of the widespread vasodilation and fluid loss caused by the activation of B2 receptors.

d) Therapeutic Targeting of the Kinin System

With kinins, particularly bradykinin, playing a pivotal role in inflammation, pain, and vascular disease, therapeutic strategies involving the manipulation of the kinin system have gained increasing attention for the treatment of diverse conditions. For instance, kinin receptor antagonists, especially the B2 receptor antagonists, have been proposed as therapeutic agents for conditions such as chronic pain, hypertension, and vascular disease.

These therapies are designed to reduce the excessive inflammatory and pain responses of kinin release while maintaining the useful effects of kinins in normal physiological processes. B1 receptor antagonists are also being explored as potential treatments for diseases in which the inflammatory response is abnormally triggered, including autoimmune diseases, chronic inflammatory diseases, and nerve injury. By acting on both B1 and B2 receptors, these treatments may bring relief in diseases like rheumatoid arthritis, osteoarthritis, and sickle cell disease where excessive pain and inflammation are the features.

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

5.1.4. Prostaglandins

Prostaglandins are biologically active lipid molecules derived from the arachidonic acid, a polyunsaturated fatty acid. They belong to a larger group of bioactive lipids known as eicosanoids, which also comprise leukotrienes and thromboxane's. Prostaglandin synthesis is through the enzymatic activity of the cyclooxygenase enzymes (COX-1 and COX-2) that convert arachidonic acid into a variety of prostaglandin intermediates. These intermediates are then metabolized to yield various prostaglandins with varied physiological and pathological functions. Prostaglandins are extremely active and tissue-specific in their effects, and therefore they are prime regulators of various biological processes like inflammation, pain, fever, reproductive function, and vascular tone.



Figure 4: Prostaglandins

- **Physiological and Pathophysiological Functions of Prostaglandins**

Prostaglandins have varied physiological actions, most of which are essential to homeostasis but also can lead to disease under conditions of overproduction. PGE2 and PGI2 (prostacyclin), for instance, both are powerful vasodilators. They cause the smooth muscle of vascular walls to relax, resulting in elevated blood flow and reduced blood pressure. PGE2 is also a primary fever-producing agent and contributes to pain sensitization, and therefore it is essential to the body's reaction to inflammation. In diseases such as arthritis or rheumatoid arthritis, excess production of PGE2 causes pain, swelling, and fever, which are the typical symptoms of these

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

conditions. PGI2, in addition to its vasodilating action, prevents platelet aggregation, and hence it is protective against too much blood clotting [13].

In contrast, PGF2α (prostaglandin F2 alpha) has a role in uterine contractions and is at the heart of reproductive health. It has a central role in the menstrual cycle and labor, whereby its release induces contraction of the smooth muscle in the uterus to result in childbirth. Dysregulation of PGF2α can lead to dysmenorrhea (painful menstruation) and labor complications. In addition, thromboxane A2 (TXA2), another significant member of the eicosanoid family, enhances platelet clumping and produces vasoconstriction. Because of this, it is an essential contributor to hemostasis—the mechanism which inhibits pathological blood loss from injury. At the same time, overproduction of TXA2 can cause thrombosis and vascular illnesses, such as heart attacks or strokes, through the stimulation of blood clot development.

- **Prostaglandins in Pathological Conditions**

Prostaglandins play an important role in numerous pathological conditions, particularly those associated with inflammation, pain, and fever. Overproduction of prostaglandins has been implicated in a number of chronic diseases. For instance, in arthritis and rheumatoid arthritis, elevated synthesis of PGE2 plays a key role in joint pain, swelling, and stiffness, which are classic symptoms of these inflammatory disorders. In a similar fashion, in endometriosis, where there is growth of endometrial tissue outside of the uterus, excessive prostaglandin synthesis results in inflammation and pain of the pelvic organs. Prostaglandins contribute to gastritis and peptic ulcers too, as their activity can undermine gastric mucosal integrity, weakening the stomach lining and making it susceptible to attacks from gastric acid.

Moreover, prostaglandins play a role in cancer biology, where they have been reported to enhance tumor growth, angiogenesis (development of new blood vessels), and metastasis (cancer spread to other locations in the body). The pro-inflammatory condition generated by increased prostaglandin levels in some cancers can facilitate tumor growth. For instance, in colorectal cancer, elevated levels of PGE2 are linked with increased tumorigenesis risk. Therefore, prostaglandins are potential targets for cancer treatment to avoid or reduce tumor growth.

- **Therapeutic Modulation of Prostaglandins**

Since they play a central role in inflammation, pain, and other disease states, prostaglandins are prime targets for therapeutic intervention. Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and aspirin are commonly used to block the activity of COX enzymes

(COX-1 and COX-2), thus inhibiting the production of prostaglandins. By reducing prostaglandin synthesis, NSAIDs relieve pain, inflammation, and fever, making them useful for the treatment of conditions such as arthritis, musculoskeletal pain, and headache. The use of NSAIDs is frequently limited by their gastrointestinal side effects, including ulcers and bleeding, caused by inhibition of COX-1, an enzyme that has a protective function in the stomach lining.

To more specifically treat prostaglandin-related disorders, prostaglandin analogues have been created. For example, misoprostol, a synthetic prostaglandin E1 analog, is used to prevent gastric mucosal protection, particularly for patients needing chronic NSAID treatment. Misoprostol is able to sustain the integrity of the stomach lining by enhancing the production of mucus and lowering gastric acid output. Latanoprost, a synthetic analogue of prostaglandin, is also applied in glaucoma treatment to lower intraocular pressure. Latanoprost functions by enhancing the aqueous humor outflow from the eye, which decreases the chance of optic nerve injury, which is typical of glaucoma.

5.1.5. Opioid Autocoids (Endogenous Opioid Peptides)

Endogenous opioid peptides—such as endorphins, enkephalins, and dynorphins—are peptide molecules that exist naturally in the body and play a key part in the pain modulation, stress response, stabilization of mood, and immune defense of the organism. These peptides are produced by the cleavage of precursor proteins and act through specific opioid receptors (μ, κ, and δ), which are found dispersed throughout the central nervous system (CNS) and peripheral tissues. Every class of opioid peptide is linked to unique physiological roles and plays an important role in the body's innate analgesic system. The endogenous opioid system also serves as an essential defense against pain, governing the body's response to physical and emotional stresses and maintaining equilibrium between mood and emotional states.

- **The Role of Opioid Receptors and Their Functions**

The μ-receptors (mu receptors) are arguably the most widely recognized and are mostly accountable for analgesia (pain relief), respiratory depression, sedation, and the feeling of euphoria. The receptors mediate the body's strongest natural pain-relieving processes and are also part of the response to acute and chronic pain. For instance, upon injury or stress, endorphins get released and bind to μ-receptors to cause analgesia, preventing the perception

of pain and inducing a sense of well-being. Excessive activation of the μ-receptors is, however, implicated in respiratory depression, a toxic side effect that could be lethal with overdose.

Conversely, κ-receptors (kappa receptors) are responsible mainly for spinal analgesia but also for the generation of dysphoria—a condition of discomfort or dissatisfaction. Stimulation of κ-receptors can decrease the perception of pain in the spinal cord but also lead to undesirable states of mind, making their function in mood control more complicated. Dysphoria can be a disruption to the desired euphoric effect of opioid peptides, and such an adverse effect is one explanation for why κ-receptor agonists are used less frequently in clinical practice to treat pain. Nevertheless, dynorphins that bind preferentially to κ-receptors are thought to be centrally involved in stress responses of the body and the modulation of mood.

The δ-receptors (delta receptors) play a main role in the modulation of emotional response, mood, and the emotional component of pain. δ-receptors activation has been found to induce analgesic action, especially in chronic pain, and to help stabilize mood. The exact mechanisms of δ-receptors in mood disorders, however, are only beginning to be investigated, with initial work indicating their role in the modulation of depression, anxiety, and emotional well-being. Therefore, δ-receptors might become therapeutic targets for mood disorders with resistance to other therapy.

- **Physiological and Pathophysiological Functions of Opioid Peptides**

Endogenous opioid peptides play a crucial role in the body's natural mechanism of defense against pain and stress. They bring about pain relief in reaction to physical trauma, emotional stress, and intense physical exertion like exercise. This is a common phenomenon known as the "runner's high" and results from the release of endorphins, which bind to the μ-receptors to cause euphoria and analgesia. This natural pain management system is activated not just for injury but also for stress and exercise, so the body can tolerate pain and function at best.

But changes in the opioid system can lead to pathological states. For instance, chronic pain, especially pain lasting longer than the projected healing time following injury, can be caused by malfunction in the opioid system. In this situation, the body cannot release sufficient endogenous opioids to effectively suppress pain, or the opioid receptors become desensitized as a result of prolonged pain stimuli, and the system becomes resistant to opioids. Likewise, mood disorders such as depression and anxiety can be caused by dysregulation of opioid peptides because these molecules are implicated in the regulation of emotion. Changes in the

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

functioning of the δ-receptors, for instance, may compromise the body's capacity to regulate emotions, leading to the symptoms of these disorders [14].

Also, opioid addiction is a significant public health problem that occurs when repeated, excessive stimulation of the opioid system takes place. Opioid drug overuse, for instance, morphine or heroin, provokes changes in the opioid receptors, commonly causing tolerance (in need of increasing amounts for equivalent effect) and reliance. When the body becomes dependent on external opioids, the endogenous opioid peptide production may diminish, further worsening the demand for opioid drugs and perpetuating addiction.

- **Therapeutic Use of Opioids and the Challenges of Abuse**

Opioid peptides play a well-established function in pain relief. Opioid receptor agonists, including morphine, fentanyl, and hydrocodone, are commonly utilized in clinical settings to produce analgesia for moderate to severe pain, particularly in postoperative and cancer patients. These agents exert their action by binding to the μ-receptors of the CNS, acting like endogenous opioids and thus producing relief from pain. But using opioid drugs for pain relief comes with serious risks, such as addiction, tolerance, and respiratory depression—a deadly side effect. Opioid tolerance and dependence are a long-documented issue in chronic pain treatment, and this has prompted increasing concerns over the opioid crisis in most nations.

As a counter measure to the hazards of opioid overdose, opioid antagonists such as naloxone have been designed. Naloxone achieves its effect by binding to the same receptors where opioids bind without activating them and thus reversing the action of opioid overdose, notably respiratory depression. It is normally administered in case of emergency in order to prevent death in overdose victims of opioids. Along with naloxone, opioid antagonists like naltrexone are applied in the therapy of opioid dependency. Naltrexone obstructs the receptors of opioids to inhibit the pleasurable effects of opioid drugs and to enable the individuals to remain sober during recuperation.

5.2. PHARMACOLOGICAL AGENTS ACTING ON AUTOCOIDS

Autocoids, or local hormones, are a collection of biologically active molecules with strong effects at the site of synthesis or action. They include histamine, serotonin, kinins, prostaglandins, and opioid peptides. Autocoids play crucial roles in numerous physiological functions like immune function, blood pressure regulation, modulation of pain, and neurotransmission. Because of their general and vital influences on the body, therapeutic

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

treatment tends to be directed at autocoid pathways in order to address such conditions as allergic reactions, inflammatory disorders, gastrointestinal illness, and pain. This chapter discusses the key drug classes that alter the activity of histamine, serotonin [15], prostaglandins, and kinins, and highlights the mechanism of action and clinical use.

5.2.1. Antihistamines (H1 and H2 Blockers)

Antihistamines represent a group of drugs that antagonize the action of histamine, one of the major autocoids that takes part in numerous physiological responses including inflammation, immune reaction, and secretion of gastric acid. Histamine exerts its action mainly through four receptor varieties: H1, H2, H3, and H4, that are localized in various tissues and organs. Of these, antagonists of H1 and H2 receptors are used most frequently in clinical practice, most notably in the treatment of allergic reactions and gastric pathology.

H1 Receptor Antagonists (H1 Blockers)

H1 receptor antagonists, or antihistamines, are medications which inhibit the H1 receptor-mediated effects of histamine. They are used extensively in the management of allergies, since histamine is centrally involved in the inflammatory response of allergic reactions like hay fever, urticaria (hives), and conjunctivitis (inflammation of the eye). When histamine is attached to H1 receptors on many different cells, it provokes symptoms such as itching, swelling, bronchoconstriction, and vascular permeability. Antihistamines can relieve these symptoms by blocking the H1 receptor.



Figure 5: H1 Receptor Antagonists

First-Generation H1 Antagonists:

- First-generation antihistamines are generally lipophilic, thereby easily crossing the blood-brain barrier to exert central nervous system (CNS) effects. Sedation or sleepiness is the most frequent CNS effect, which makes these medications useful as hypnotics. Crossings of the blood-brain barrier by these medications, however, may result in other CNS side effects, including impaired coordination and cognitive dysfunction.
- They are also anticholinergic in nature, i.e., they can prevent the action of acetylcholine, a neurotransmitter involved in a number of functions in the body. This can result in undesirable side effects such as dry mouth, blurred vision, constipation, and retention of urine. Examples of drugs in this group are diphenhydramine, chlorpheniramine, and hydroxyzine.
- Because of their sedative effects and anticholinergic action, first-generation antihistamines are usually regarded as not being long-term friendly, particularly for individuals who must stay awake or drive vehicles and machinery.

Second-Generation H1 Antagonists:

- Second-generation antihistamines like loratadine, cetirizine, and fexofenadine are formulated to produce fewer CNS side effects. They are more peripheral H1 receptor-selective and have less capacity to cross the blood-brain barrier, which reduces the sedative effects that are commonly associated with first-generation antihistamines.
- These medications have fewer chances of producing anticholinergic effects and are thus safe for long-term use, even in patients who need to prevent sedation, like motorists and workers operating machinery. Second-generation antihistamines are also commonly used for the treatment of seasonal allergies, hay fever, and other allergic diseases due to the fact that they produce relief while not inducing sleepiness.

First- and second-generation H1 antagonists are equally effective in inhibiting capillary permeability, smooth muscle contraction, and activation of sensory nerves. This leads to relief of symptoms of allergy like itching, swelling, and sneezing, bronchodilation, and decreased vascular leakage, which are major elements of the allergic inflammatory process.

H2 Receptor Antagonists (H2 Blockers)

While H1 receptor antagonists are employed mainly for allergic conditions, H2 receptor antagonists (or H2 blockers) are employed to treat gastric conditions due to overproduction of

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

acid. Histamine stimulates the H2 receptors on the parietal cells of the stomach, leading to the secretion of gastric acid. In conditions where there is excess acid production, like peptic ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome, the H2 receptor blockade can prevent acid secretion and relieve symptoms.

H2 blockers include drugs such as ranitidine, famotidine, and cimetidine. These drugs operate by binding specifically to the H2 receptors in the stomach, thus blocking the action of histamine on the parietal cells and minimizing gastric acid secretion. Consequently, these drugs are able to relieve symptoms of heartburn, acid reflux, and stomach ulcers by facilitating healing of the injured gastric tissue and discouraging further irritation.

- Ranitidine and famotidine are two examples of more widely used H2 blockers because they are stronger and have fewer side effects than older medications such as cimetidine. Cimetidine has been implicated in numerous drug interactions and endocrine side effects (e.g., impotence and gynecomastia) as a result of its action on some liver enzymes.
- By lowering basal and stimulated acid secretion, H2 blockers are useful in treating conditions where acid reflux is a cause of discomfort or damage to the stomach and esophagus lining.

Mechanism of Action of Antihistamines

Antihistamines act by occupying histamine receptors, thus blocking histamine from binding to them and triggering its usual physiological effects. H1 receptor blockers block histamine-mediated allergic reactions like bronchoconstriction, vascular permeability, and itching. H2 receptor blockers decrease gastric acid secretion by blocking histamine from binding to H2 receptors on parietal cells, thus lowering acid-related gastrointestinal symptoms.

Clinical Uses of Antihistamines

- H1 blockers are most commonly applied to alleviate allergic disorders, such as seasonal allergies, hay fever, conjunctivitis, urticaria (hives), and rhinitis. They can also be utilized for alleviating the symptoms of motion sickness and for treating insomnia because they possess sedative effects.
- H2 blockers are prescribed for the curing of gastric ulcers, GERD, acid reflux, and other related diseases with excess acid production. They are particularly helpful in bringing relief from heartburn and in curing gastric ulcers.

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

5.2.2. 5-HT Antagonists (Serotonin Receptor Blockers)

Serotonin (5-HT) is a neurotransmitter involved in many physiological functions, such as mood, digestion, and vasoconstriction. Serotonin antagonists are agents that inhibit serotonin receptors, aimed at conditions in which excess serotonergic activity produces unwanted symptoms. Such conditions are nausea, vomiting, migraine, and some gastrointestinal diseases. The different serotonin receptors, such as 5-HT3, 5-HT2, and 5-HT1, transduce different parts of the effect of serotonin, and drugs that act on these receptors are used in the treatment of these diseases.

1) 5-HT3 Receptor Antagonists

5-HT3 receptors are found mainly in the gastrointestinal tract and brainstem chemoreceptor trigger zone, both of which play a role in the vomiting reflex. When serotonin acts on these receptors, it induces the sensation of nausea and vomiting, especially due to chemotherapy, surgery, or some other medical conditions. 5-HT3 receptor antagonists inhibit serotonin's effect on these receptors, thereby decreasing the frequency of nausea and vomiting.

5-HT3 receptor antagonists that are commonly used include ondansetron, granisetron, dolasetron, and palonosetron. These medications work very effectively at preventing chemotherapy-induced nausea and vomiting (CINV) [16], which occurs as a typical side effect in chemotherapy treatments. They are used to prevent nausea and vomiting related to postoperative procedures and treat nausea in various gastrointestinal diseases like irritable bowel syndrome (IBS).

- **Ondansetron**: This is one of the most widely used antiemetics, particularly for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. It works by selectively blocking the 5-HT3 receptors in the brain and gut, which helps to stop the signals that lead to vomiting.
- **Granisetron**: Similar to ondansetron, granisetron is another 5-HT3 receptor blocker employed for the prevention of CINV and PONV. Granisetron possesses a longer half-life than ondansetron, which may prove beneficial in some clinical settings.
- **Palonosetron**: This drug is a second-generation 5-HT3 antagonist, known for its long-lasting effects. It is particularly effective in managing delayed nausea associated with chemotherapy.

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

By blocking the 5-HT3 receptors, these medications slow down vomiting and nausea caused by chemotherapy, surgery, or gastrointestinal upset. 5-HT3 antagonists are among the most effective drugs for CINV.

2) 5-HT2 Receptor Antagonists

The 5-HT2 receptor is implicated in a range of physiological responses such as mood regulation, vascular tone, and gastrointestinal motility. 5-HT2 receptor antagonists inhibit these receptors, thus diminishing the effects of serotonin on vascular constriction and inflammatory processes.

Cyproheptadine and ketanserin are examples of 5-HT2 receptor antagonists:

- **Cyproheptadine**: This medication is both an antihistamine and a 5-HT2 receptor antagonist. It is administered to manage a number of conditions, such as serotonin syndrome due to an overabundance of serotonin in the body, carcinoid syndrome, and prophylaxis of migraine. Cyproheptadine is also employed as an appetite stimulant in cases such as anorexia and cachexia since it has the ability to stimulate increased appetite.
- **Ketanserin**: This medication is utilized to treat illnesses of serotonergic excess, including serotonin syndrome. It also can be used in treating hypertension in specific patients, since it is a vasodilator due to its action as a blocker of 5-HT2 receptors on smooth muscle cells. It has been employed in the management of carcinoid syndrome as well, relieving flushing and other signs resulting from excessive release of serotonin from carcinoid tumors.

In serotonin syndrome, where heightened serotonin activity causes hyperthermia, autonomic instability, and neuromuscular hyperactivity, 5-HT2 antagonists counteract these symptoms by blocking the surplus serotonin at receptor sites. The drug of first choice in this situation is frequently cyproheptadine.

3) 5-HT1 Receptor Modulators (Triptans)

Although not strictly an antagonist, 5-HT1 receptor agonists are a key drug class in the acute treatment of migraines. Triptans, e.g., sumatriptan, rizatriptan, and zolmitriptan, are selective 5-HT1 receptor agonists that cross the blood-brain barrier and bind to serotonin receptors in the brain, namely the 5-HT1B and 5-HT1D subtypes. They cause vasoconstriction of intracranial blood vessels and suppression of the release of pro-inflammatory neuropeptides, both of which contribute to the relief of migraine symptoms.

The action mechanism of triptans includes:

- **Vasoconstriction:** Triptans cause vasoconstriction of the cranial blood vessels, which is believed to reverse the dilated blood vessels responsible for the headache phase of a migraine.
- **Blockade of Neurotransmitter Release:** They also block the release of calcitonion gene-related peptide (CGRP) and other neuropeptides, which are involved in the pathogenesis of migraine-related inflammation and pain.

Triptans are generally reserved for the acute therapy of migraines, with their being able to cause dramatic relief from headache, nausea, and other related symptoms. Triptans are not employed in the prophylaxis of migraine but can abort migraine when already initiated.

- **Sumatriptan:** One of the most widely used triptans, sumatriptan comes in several forms, including oral tablets, subcutaneous injection, and nasal spray, so that flexibility is possible based on the intensity of the migraine attack.
- **Rizatriptan:** This medication has an extremely fast onset of action, and is often used when quick relief is desired.
- **Zolmitriptan:** Like sumatriptan, zolmitriptan is available in oral and nasal spray forms.

Although triptans are very effective, they are not for everyone. They are contraindicated in patients with some cardiovascular disease, as the vasoconstrictive properties may have the potential to worsen underlying heart disease or hypertension.

5.2.3. Prostaglandin Analogues and Inhibitors

Prostaglandins are a family of arachidonic acid-derived lipid compounds, which are found in the cell membrane of numerous tissues. They are produced via the activity of the COX enzymes, which come in two predominant isoforms: COX-1 and COX-2. Prostaglandins have extensive physiological actions and play a crucial function in numerous corporeal functions, such as:

- **Vasodilation:** Relaxation of blood vessel walls, resulting in a reduction in blood pressure.
- **Fever:** Mediating the hypothalamic response to pyrogens (agents that cause fever).
- **Pain Sensitization:** Prostaglandins increase the sensitivity of pain receptors, leading to inflammation and pain.

- **Smooth Muscle Contraction:** Facilitating functions such as labor and gastrointestinal motility.

Since prostaglandins play a crucial role in numerous physiological and pathological events, prostaglandin analogs and prostaglandin inhibitors have been synthesized for their therapeutic applications, especially for the control of inflammation, pain, gastrointestinal mucosal protection, and regulation of ocular pressure.

➢ **Prostaglandin Inhibitors (NSAIDs)**

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) constitute a group of drugs that are inhibitors of COX enzymes and, as a result, diminish the synthesis of prostaglandins. Inhibiting prostaglandin synthesis, in turn, leads to the lowering of inflammation, pain, fever, and thrombosis.

- COX-1 is constitutively expressed in a variety of tissues and serves to keep all of these aspects of normal physiological function running within their "norm.".
- COX-2, however, is generally induced by inflammation and tissue damage to produce prostaglandins that cause pain and inflammation.

Inhibition of COX-1 and COX-2 results in the decrease of inflammatory prostaglandins and thromboxanes. Inhibition of COX-1, however, results in unwanted side effects like gastric irritation and ulceration, as well as renal impairment.

NSAIDs include such popular medications as aspirin, ibuprofen, diclofenac, and naproxen, each utilized for their anti-inflammatory, analgesic, and antipyretic actions. Nevertheless, chronic administration of non-selective NSAIDs leads to gastrointestinal toxicity, that is, ulcers and bleeding, mainly by virtue of inhibition of COX-1.

➢ **Selective COX-2 Inhibitors**

Selective COX-2 inhibitors like celecoxib were invented to offer the anti-inflammatory and analgesic effects of old NSAIDs while reducing the gastrointestinal side effects resulting from COX-1 inhibition. The medication selectively inhibits the COX-2 enzyme, which primarily contributes to inflammation and pain [17], without significantly affecting COX-1 (that is crucial to lining the stomach and maintaining platelet function). Consequently, COX-2 inhibitors produce less gastric irritation and are usually used for long-term treatment in diseases such as arthritis, chronic pain, and acute inflammation. Nevertheless, they have been linked with a possible increased risk of cardiovascular events, including heart attacks and strokes, because of their selective inhibition of COX-2 and its effect on vascular homeostasis.

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

- **Prostaglandin Analogues**

Prostaglandin analogues are man-made substances that simulate the activities of natural prostaglandins. Prostaglandin analogues are applied to address particular physiological actions, including protection of the gastrointestinal tract, reduction of ocular pressure, contraction of the uterus, and erectile dysfunction. The three primary categories of prostaglandin analogues and their applications are:

- **Misoprostol (PGE1 Analogue)**

Misoprostol is a prostaglandin E1 analogue and is used mainly for gastric protection, particularly in patients who are on NSAIDs, which can enhance the risk of gastric ulcers and bleeding. Misoprostol acts by:

- **Increasing mucosal defense**: It induces the formation of mucus and bicarbonate in the lining of the stomach, protecting it from the destructive action of gastric acid.
- **Enhancing blood supply to the stomach:** It induces gastric mucosal vasodilation, again contributing to gastric protection.

Apart from its application in gastric ulcer prevention, misoprostol is also utilized for:

- **Induction of labor:** Misoprostol can cause uterine contractions and is occasionally utilized in the induction of labor in some obstetric situations.
- **Medical abortion:** Misoprostol, usually combined with mifepristone, is employed for medical abortion, in which it causes the uterus to contract and pass out the pregnancy tissue.

- **Latanoprost (PGF2α Analogue)**

Latanoprost is a prostaglandin F2α (PGF2α) analog that works in the treatment of glaucoma and ocular hypertension.

- **Enhancing aqueous humor outflow:** Latanoprost lowers intraocular pressure by increasing the outflow of the aqueous humor (the fluid within the eye), which is the most important way to manage conditions such as glaucoma. By lowering intraocular pressure, latanoprost prevents damage to the optic nerve that may be caused by glaucoma.

Latanoprost is usually given as an eye drop, and is generally well tolerated. The most frequent side effects are eye irritation, eye color change (increase in pigmentation), and eyelash growth.

➢ **Alprostadil (PGE1)**

Alprostadil is a prostaglandin E1 (PGE1) analogue employed in various clinical applications. It acts by:

- **Vasodilation:** Alprostadil induces the relaxation of smooth muscles of blood vessels, resulting in vasodilation and enhanced blood supply. The characteristic is employed to cure different disorders of impaired blood supply.
- **Ductus arteriosus patency maintenance:** In patients with congenital heart defects like ductal-dependent congenital heart disease, alprostadil is administered to maintain patency of the ductus arteriosus, which ensures proper circulation until surgery is possible.
- **Erectile dysfunction:** Alprostadil is also applied in the treatment of erectile dysfunction (ED). It is commonly given intracavernously (into the penis) to cause erections by stimulating blood flow to the erectile tissue.

Alprostadil is also, on occasion, prescribed in addition to other sexual dysfunction treatments when oral agents such as PDE5 inhibitors (e.g., sildenafil) fail.

5.2.4. Kinin Modulators

Kinins, particularly bradykinin, are peptide molecules with important roles in numerous physiological processes such as vasodilation, pain perception, and inflammation. Bradykinin is generated by the kallikrein-kinin system, and it produces its effects by binding to particular kinin receptors on target tissues [18]. It is especially renowned for its strong capacity to cause vascular permeability, leading to swelling and pain in inflammatory reactions. While there are no direct kinin antagonists in common use, a number of pharmacological agents affect the kinin system by raising bradykinin levels or by blocking its action, depending on the desired therapeutic effect [19].

➢ **Angiotensin-Converting Enzyme (ACE) Inhibitors**

Angiotensin-Converting Enzyme (ACE) inhibitors, including enalapril, captopril, and others, are commonly used in the treatment of hypertension and heart failure. These medications exert their main effect by inhibiting the angiotensin-converting enzyme (ACE), which possesses two essential functions:

1**. Converting angiotensin I to angiotensin II** (a very strong vasoconstrictor that raises blood pressure).

2. **Degradation of bradykinin:** ACE is responsible for the degradation of bradykinin. By inhibiting ACE, these drugs raise the level of bradykinin, which results in vasodilation.

The vasodilating action of increased bradykinin levels is useful in lowering blood pressure and enhancing blood flow, rendering ACE inhibitors useful in the management of hypertension, congestive heart failure, and renal disease. They additionally have favorable actions on the remodeling process of the heart and can prevent or treat such diseases as diabetic nephropathy.

But the rise in bradykinin can also lead to unwanted side effects, such as:

- **Dry cough:** The presence of bradykinin in the respiratory system may trigger the cough reflex, a frequent side effect among users of most ACE inhibitors.
- **Angioedema:** Hyperbradykininemia may cause swelling of the deeper dermal layers, especially in the face, lips, and airway, and can be fatal if it causes laryngeal swelling.

Due to these side effects, certain patients are forced to change to angiotensin II receptor blockers (ARBs), which do not modulate the level of bradykinin in the same manner, although they also maintain blood pressure under control.

- **Bradykinin B2 Receptor Antagonists**

The B2 bradykinin receptor is the primary receptor involved in mediating the effects of bradykinin, such as vasodilation, increased vascular permeability, and pain. Through binding to this receptor, bradykinin triggers downstream signaling pathways that lead to the above physiological activities.

Icatibant, a B2 receptor antagonist, is a drug that is intended to inhibit the action of bradykinin at the B2 receptor. Icatibant is mainly applied in the management of hereditary angioedema (HAE), a rare genetic condition that involves recurrent episodes of severe swelling in different areas of the body, such as the face, extremities, and airway. The disease is a result of overproduction of bradykinin during an attack, resulting in hyperpermeability of vessels and leakage of fluid into tissues, causing swelling and pain.

By inhibiting the B2 receptor, icatibant stops bradykinin from producing its effects and thus helps in reducing the pain and swelling that is caused by hereditary angioedema. The medication is given subcutaneously and is most useful in the management of acute HAE attacks.

The administration of icatibant decreases the morbidity of this disease and gives symptomatic relief in attacks. It is a targeted treatment that acts on blocking the definite pathway that causes the symptoms of HAE and is thus a useful agent in the clinical treatment of this disorder.

- **Kallikrein Inhibitors**

Kallikrein inhibitors, like ecallantide, inhibit the enzyme kallikrein, which is the enzyme that produces bradykinin from kininogen. Kallikrein is a central part of the kinin-kininogen system, where it converts kininogen to bradykinin. Inhibiting kallikrein decreases the production of bradykinin and counteracts the effects of overproduction of bradykinin.

Ecallantide is a kallikrein inhibitor that is employed in the treatment of hereditary angioedema (HAE). In HAE, there is an uncontrolled generation of bradykinin, resulting in attacks of swelling and pain. Ecallantide prevents the generation of excess bradykinin and thereby the vascular leakage and swelling experienced in HAE attacks.

- Ecallantide is given subcutaneously and is effective in acute HAE attacks, controlling symptoms such as angioedema and pain.
- In contrast to icatibant, which inhibits the effect of bradykinin at the receptor level, ecallantide blocks the generation of bradykinin entirely, providing a complementary therapeutic mechanism in the treatment of HAE.

This drug class is significant in that they interrupt the kallikrein-kinin pathway and prevent overproduction of bradykinin, thereby relieving the acute manifestations of hereditary angioedema [20]. Kinins, especially bradykinin, are implicated in a variety of physiological processes such as vasodilation, pain and inflammation. Although the effects of bradykinin are generally useful for normal physiological functions, overproduction or uncontrolled production of bradykinin can result in pathological states like hereditary angioedema and acute inflammatory reactions.

A number of pharmacological agents regulate the kinin system to yield therapeutic advantages:

- ACE inhibitors (such as enalapril and captopril) elevate bradykinin levels by blocking ACE, causing vasodilation and reduced blood pressure but may also result in side effects such as dry cough and angioedema.
- Bradykinin B2 receptor antagonists, such as icatibant, inhibit the action of bradykinin and are utilized in the treatment of hereditary angioedema to decrease swelling and pain.

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

- Kallikrein inhibitors like ecallantide inhibit the production of bradykinin and are utilized in the treatment of hereditary angioedema to alleviate swelling and pain symptoms.

These therapeutic strategies provide effective treatment for conditions that arise from overactive bradykinin, specifically for hereditary angioedema, and provide specific interventions to treat the symptoms of vascular leakage and pain that accompany the disease.

DOI 10.5281/zenodo.15826880 https://doi.org/10.5281/zenodo.15826881

REFERENCES

1. Eilers, H., & Yost, S. (2018). General anesthetics. *Basic & clinical pharmacology*, *14*.
2. Maher, T. J. (2012). Anesthetic agents: General and local anesthetics. *Foye's Princ. Med. Chem., 7th ed., Lippincott Williams & Wilkins*, 508-539.
3. Barends, C., & Absalom, A. (2016). Anxiolytics, sedatives and hypnotics. *Anaesthesia & Intensive Care Medicine*, *17*(8), 411-417.
4. Abdeshahi, S. K., Hashemipour, M. A., Mesgarzadeh, V., Payam, A. S., & Monfared, A. H. (2013). Effect of hypnosis on induction of local anaesthesia, pain perception, control of haemorrhage and anxiety during extraction of third molars: a case–control study. *Journal of Cranio-Maxillofacial Surgery*, *41*(4), 310-315.
5. Peimani, A., Irannezhad, M., & Ahmadi, A. M. (2017). Comparing the effect of hypnosis and local anesthesia injection on induction of local anesthesia, anxiety, hemorrhage and pain control during tooth extraction. *Journal of Research in Medical and Dental Science*, *5*(4), 44-9.
6. Harbell, M. W., Dumitrascu, C., Bettini, L., Yu, S., Thiele, C. M., & Koyyalamudi, V. (2021). Anesthetic considerations for patients on psychotropic drug therapies. *Neurology International*, *13*(4), 640-658.
7. Meerts, C., & Absalom, A. (2013). Anxiolytics, sedatives and hypnotics. *Anaesthesia & Intensive Care Medicine*, *14*(8), 355-360.
8. Chung, K. H., Cho, M. S., & Jin, H. (2017). Perioperative hypertension management during facelift under local anesthesia with intravenous hypnotics. *Archives of Plastic Surgery*, *44*(04), 276-282.
9. Pérez-García, S., Acosta-Ibarra, J., Ruiz-Roca, J. A., Añez, C., & Gargallo-Albiol, J. (2024). Comparison of hemodynamic changes with general or local anesthesia during dental treatment in pediatric patients: A prospective clinical study. *Special Care in Dentistry*, *44*(2), 563-574.
10. Pateron, B., Bakhos, D., LeLouarn, A., Bordure, P., Grayeli, A. B., Godey, B., & Lescanne, E. (2016). Local anaesthesia and conscious sedation for cochlear

implantation: experience with 20 patients. *The Journal of Laryngology & Otology*, *130*(2), 151-156.

11. Steinkraus, K. C., Feldmann, H., Hunold, L. S., Graf, S., Dörr-Harim, C., Nasir, N., ... & Hüttner, F. J. (2024). Impact of virtual reality hypnosedation on perioperative pain and anxiety in port implantation under local anesthesia: a randomized controlled pilot trial (VIP Trial). *Perioperative Medicine*, *13*(1), 101.
12. Ing, E. B., Philteos, J., Sholohov, G., Kim, D. T., Nijhawan, N., Mark, P. W., & Gilbert, J. (2019). Local anesthesia and anxiolytic techniques for oculoplastic surgery. *Clinical Ophthalmology (Auckland, NZ)*, *13*, 153.
13. Neri, S., Mastroianni, G., Gardella, E., Aguglia, U., & Rubboli, G. (2022). Epilepsy in neurodegenerative diseases. *Epileptic Disorders*, *24*(2), 249-273.
14. Cano, A., Fonseca, E., Ettcheto, M., Sánchez-López, E., de Rojas, I., Alonso-Lana, S., ... & Ruíz, A. (2021). Epilepsy in neurodegenerative diseases: related drugs and molecular pathways. *Pharmaceuticals*, *14*(10), 1057.
15. Callari, A., & Miniati, M. (2019). Clinical and therapeutic challenges when psychiatric disorders occur in neurological diseases: A narrative review. *Current Psychiatry Research and Reviews Formerly: Current Psychiatry Reviews*, *15*(2), 132-142.
16. Sinanović, O. (2020). Psychiatric disorders in neurological diseases. *Mind and Brain: Bridging Neurology and Psychiatry*, 65-79.
17. Maristany, A. J., Sa, B. C., Murray, C., Subramaniam, A. B., & Oldak, S. E. (2024). Psychiatric manifestations of neurological diseases: a narrative review. *Cureus*, *16*(7).
18. De Haan, P., Klein, H. C., & ’t Hart, B. A. (2017). Autoimmune aspects of neurodegenerative and psychiatric diseases: a template for innovative therapy. *Frontiers in Psychiatry*, *8*, 46.
19. Seritan, A. L. (2023). Advances in the diagnosis and management of psychotic symptoms in neurodegenerative diseases: A narrative review. *Journal of Geriatric Psychiatry and Neurology*, *36*(6), 435-460.
20. Gupta, R., Advani, D., Yadav, D., Ambasta, R. K., & Kumar, P. (2023). Dissecting the relationship between neuropsychiatric and neurodegenerative disorders. *Molecular Neurobiology*, *60*(11), 6476-6529.